349-57-5

Basic information

• Product Name: 3-Nitro-5-(trifluoromethyl)phenol
• Synonyms: 3-HYDROXY-5-NITROBENZOTRIFLUORIDE;3-NITRO-5-(TRIFLUOROMETHYL)PHENOL;3-Hydroxy-5-nitrobenzotrifluoride ,95%;3-Nitro-5-(trifluoromethyl)phenol, 3-Hydroxy-5-(trifluoromethyl)nitrobenzene
• CAS NO: 349-57-5
• Molecular Formula: C₇H₄F₃NO₃
• Molecular Weight: 207.11
• Product Categories: Alcohols and Derivatives;Aromatic Phenols;Phenol&Thiophenol&Mercaptan
• Mol File: 349-57-5.mol
• Article Data: 14

Chemical Properties

• Melting Point: 89-92°C
• Boiling Point: 258.9 °C at 760 mmHg
• Flash Point: 110.4 °C
• Appearance: /
• Density: 1.554 g/cm³
• Vapor Pressure: 0.0083mmHg at 25°C
• Refractive Index: 1.507
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 7.34±0.10(Predicted)
• CAS DataBase Reference: 3-Nitro-5-(trifluoromethyl)phenol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Nitro-5-(trifluoromethyl)phenol(349-57-5)
• EPA Substance Registry System: 3-Nitro-5-(trifluoromethyl)phenol(349-57-5)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 349-57-5(Hazardous Substances Data)

Usage

General Description

3-Nitro-5-(trifluoromethyl)phenol is a chemical compound with the molecular formula C7H4F3NO3. It is a yellow crystalline solid that is primarily used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. 3-Nitro-5-(trifluoromethyl)phenol is a phenolic compound with a nitro and trifluoromethyl group attached to the benzene ring, making it useful for its electron-donating and electron-withdrawing properties. It is also used as a building block for the synthesis of various heterocyclic compounds, making it an important compound in the field of organic chemistry. However, it is important to handle this compound with care, as it is toxic if ingested or inhaled, and can cause irritation to the skin and eyes.

InChI:InChI=1/C7H4F3NO3/c8-7(9,10)4-1-5(11(13)14)3-6(12)2-4/h1-3,12H

Upstream product

• 100-02-7 4-nitro-phenol 
• 401-99-0 3,5-dinitrobenzotrifluoride 
• 454-73-9 1-fluoro-3-(trifluoromethyl)-5-nitrobenzene 
• 393-75-9 4-chloro-3,5-dinitrobenzotrifluoride 
• 328-79-0 1-methoxy-3-nitro-5-trifluoromethyl-benzene 
• 133532-73-7 3,5'-dinitro-5,5'-bis-trifluoromethyldiphenyl ether 
• 401-94-5 3-nitro-5-(trifluoromethyl)-phenylamine 

Downstream Products

• 328-79-0 1-methoxy-3-nitro-5-trifluoromethyl-benzene 
• 942076-91-7 1-[2-(3-nitro-5-trifluoromethyl-phenoxy)ethyl]-pyrrolidine 
• 1044707-66-5 1-(2-chloroethoxy)-3-nitro-5-(trifluoromethyl)benzene 
• 900254-38-8 N,N-dimethyl-2-(3-nitro-5-(trifluoromethyl)phenoxy)ethanamine 
• 1107062-37-2 1-(4-(methylsulfonyl)phenoxy)-3-nitro-5-(trifluoromethyl)benzene 
• 454-68-2 5-(trifluoromethyl)phenyl-1,3-diol 
• 1093800-44-2 C₂HF₃O₂*C₂₂H₂₅F₃N₆O₄ 
• 1093800-41-9 C₂₇H₃₃F₃N₆O₆ 
• 1093799-60-0 C₁₃H₁₆F₃NO₃*ClH 
• 1093799-61-1 C₁₁H₁₂F₃NO₃*ClH 

Relevant articles and documents

PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS

JAK1 inhibitors of structural formula (I), wherein Ar1, Ar2, Q, W, X, Y, and Z are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.

COMPOUNDS AND METHODS OF USE

Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE

The present invention provides classes of compounds, including-their pharmaceutically acceptable derivatives, useful for treating angiogenesis and related diseases such as cancer. Formula I and II wherein R is a 9- or 10-membered heterocyclyl ring selected from 7-isoquinolinyl,..2-methyl-3-oxo-2,3-dihydroindazol-6-yl, [1,6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, 1-oxo-2,3-dihydrobenzofuran-4-yl, 3-oxo-2,3-dihydrobenzofuran-5-yl, dihydro-benzodioxinyl, 6-quinazolinyl, 2-amino-6-quinazolinyl, 4-methylamino-6-quinazolinyl, 2,4-diamino-6 quinazolinyl, 3-oxo-3,4-dihydro-1,4-benzoxazin-6-yl, 2,2-difluoro-l;3-benzodioxol-5-yl and 2,2,3,3 tetrafluoro-2,3-dihydro-l,4-benzodioxin-6-yl, each of which is optionally substituted with one or more substituents selected from halo, haloakyl, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, N-dimethylamino-C1-6-alkyl, N-dimethylamino-C1-6-alkoxy, amino, alkyl-carbonylamino, morpholino-sulfonyl, amino-sulfonyl, oxazolyl, pyrrolyl,4 morpholinyl, carboxyl, cyano, and acetyl; wherein R1 in formula I is selected from unsubstituted or substituted phenyl, 5-6 membered heteroaryl, 9-10 membered bicyclic heterocyclyl and 11-14 membered tricyclic heterocyclyl, and R1 in formula II is selected from specific bicyclic heterocycles.